Tenaya therapeutics to present preclinical data on its novel engineered aav capsids for cardiac gene delivery at the esgct 29th annual congress

South san francisco, calif., oct. 04, 2022 (globe newswire) -- tenaya therapeutics, inc. (nasdaq: tnya), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today that it will present new preclinical data on its novel aav capsids for cardiac gene delivery at the 29th annual congress of the european society of gene and cell therapy (esgct), october 11 - 14, 2022 in edinburgh, scotland.
TNYA Ratings Summary
TNYA Quant Ranking